{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"84.4","upperLimit":"92.0","value":"88.8"},{"groupId":"OG001","lowerLimit":"88.1","upperLimit":"94.7","value":"92.0"}]}],"title":"Overall survival at 12 months (%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.4","upperLimit":"83.4","value":"78.9"},{"groupId":"OG001","lowerLimit":"66.9","upperLimit":"78.1","value":"73.0"}]}],"title":"Overall survival at 24 months (%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"278"}],"units":"Participants"}],"description":"Landmark Overall Survival at 1, 2, and 3 years looks at the percent of patients alive at 1, 2 and 3 year time points.\n\nOverall survival at 36 months not included to data cut off prior to 36-month timepoint.\n\nOverall survival percentage calculated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Osimertinib (AZD9291) 80 mg in combination with pemetrexed (500 mg/m2) plus either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles for 4 cycles, followed by Osimertinib (AZD9291) 80 mg QD with Pemetrexed maintenance (500 mg/m2) Q3W","id":"OG000","title":"Randomized: AZD9291 + Chemo"},{"description":"Osimertinib (AZD9291) 80mg QD.","id":"OG001","title":"Randomized: AZD9291"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set, includes all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 33 months after the first patient is randomized (maximum follow up of 34.1 months)","title":"Landmark Overall Survival (LOS) at 1, 2, and 3 Years (Randomized Component)","type":"SECONDARY","unitOfMeasure":"percent of participants"}